Results 211 to 220 of about 301,645 (308)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

A study on the impact of catastrophic health expenditure on social stability. [PDF]

Front Public Health
Huang G, Lv Y.
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Diabetic Ketoacidosis From Health Insurance-Requested Non-medical Switching. [PDF]

Cureus
Can AS, Yeakley F, Zhang Z.
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Prevalence of dual sensory impairment in Australia: a nationally representative population-based survey of Indigenous and non-Indigenous Australians. [PDF]

Lancet Reg Health West Pac
Gopinath B, Macken O, Kha R, Low G, Kapucu Y, Newall J, Waddell C, Fricke T, Yang E, Indrakumar M, Tang D, Turner A, Keay L, Liew G, Mitchell P.   +14 more
europepmc   +1 more source

Non-Life Insurance Mathematics

, 2004
openaire   +2 more sources

CSR of Japaneese Non-Life Insurers

Hokengakuzasshi (JOURNAL of INSURANCE SCIENCE), 2012
openaire   +2 more sources

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Study of Clinico-demography and Impact on Quality of Life of Patients with Scalp Pruritus. [PDF]

Indian Dermatol Online J
Varshney A, Dsouza P, Rastogi P, Arora J.   +3 more
europepmc   +1 more source